“HRT can have a transformative effect for women suffering from the worst symptoms of menopause,” says President Ksenija Pavletic. “That is why the results of these studies should not be used to persuade women against taking HRT but should trigger more research into making it safer.”
The Gedeon Richter Group, an international pharmaceutical company with Hungarian roots, is committed to women’s health. Around a third of its annual turnover is generated through the development, manufacture and sale of gynaecological drugs such as the contraceptive pill and HRT treatments.
Another 50% comes from the contract manufacture of a range of generic drugs while the remainder comes from the research and development of products for the central nervous system. Gedeon Richter France is one of a number of sales subsidiaries for the group’s products in Europe, South America and Asia.
“The pharmaceutical market is currently undergoing a geographic shift with a significant proportion of production capacity being moved to low-wage countries in Asia,” says Ms. Pavletic. “We are bucking this trend by maintaining production in Europe and focusing on speciality products.”
As well as being President of the French sales operation, Ksenija Pavletic is also CEO of Preglem in Geneva, a recently acquired subsidiary with a portfolio of women’s health products.
“Preglem specializes in treatments for uterine fibroids – benign growths in the womb that can impair fertility and cause discomfort for a lot of women,” explains Ms. Pavletic. “It is an important acquisition for us as it has a strong reputation for research and development and is currently conducting a number of clinical studies into biosimilar products that represent the current trend in gynaecological research.”
Gedeon Richter also recently acquired the gynaecological portfolio of pharma specialist Grünenthal, which will strengthen its presence in Western Europe. The French subsidiary was founded in 2012 and already generates six million EUR in sales.
“Gedeon Richter is a well-known name and strong presence in Central and Eastern Europe but a relative newcomer in Western European markets,” says Ms. Pavletic. “Our goal is to become a trustful partner in gynaecology.”